Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647450 | 0.85 | TDP1 (0.50) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Bromoethane SCHEMBL43961 | 0.82 | TDP1 (0.67) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL1374996 | 0.82 | TDP1 (0.67) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Dibromomethane SCHEMBL5329477 | 0.82 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Dibromomethane SCHEMBL7950072 | 0.82 | TDP1 (0.75) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL8532623 | 0.81 | CYP3A4 (0.46) | TDP1CYP3A4ESR1ESR2KDM4E | |
| SCHEMBL9432475 | 0.81 | CYP3A4 (0.57) | TDP1CYP3A4ESR1ESR2KDM4E | |
| 1,2-Dibromoethane SCHEMBL28837174 | 0.79 | TDP1 (0.71) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Bromomethane SCHEMBL3346 | 0.79 | TDP1 (0.80) | TDP1CYP3A4ESR1ESR2KDM4E | |
| Bromomethane SCHEMBL28892441 | 0.79 | TDP1 (0.80) | TDP1CYP3A4ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110366571-B | Modified resin and curable resin composition containing the same | 协立化学产业株式会社 | 2020-09-18 | — | — | CN | disclosed |
| CN-110366570-B | (meth) acrylate resin and curable resin composition containing same | 协立化学产业株式会社 | 2020-09-15 | — | — | CN | disclosed |
| CN-110366570-A | (methyl) acrylate and hardening resin composition comprising (methyl) acrylate | 协立化学产业株式会社 | 2019-10-22 | — | — | CN | disclosed |
| CN-110366571-A | Modified resin and hardening resin composition comprising the modified resin | 协立化学产业株式会社 | 2019-10-22 | — | — | CN | disclosed |
| EP-3013782-B1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-10-03 | — | — | EP | disclosed |
| CN-105085869-B | The liquid crystal panel encapsulant that drips | 协立化学产业株式会社 | 2017-08-29 | — | — | CN | disclosed |
| US-9708570-B2 | Organic compounds | Givaudan, S.A. (CH) | 2017-07-18 | — | — | US | disclosed |
| US-20160369205-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-12-22 | — | — | US | disclosed |
| EP-3013782-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2016-05-04 | — | — | EP | disclosed |
| CN-105085869-A | Partially esterified epoxy resin and process for production thereof | KYORITSU CHEMICAL CO LTD | 2015-11-25 | — | — | CN | disclosed |
| WO-2014205782-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2014-12-31 | — | — | WO | disclosed |
| CN-102666635-A | Partially esterified epoxy resin and method for producing the same | KYORITSU CHEMICAL CO LTD | 2012-09-12 | — | — | CN | disclosed |
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| US-4267363-A | Intermediates for a sex pheramone for yellow scale | ZOECON CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160369205-A1 | ORGANIC COMPOUNDS | PAH, AQP3, HPD | TDP1 3337/4885CYP3A4 227/4885ESR1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.